Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 5 47-5, 2003, Pages

  Nishizawa, Makoto ^a   Moore, Mary Courtney ^a   Shiota, Masakazu ^a   Gustavson, Stephanie M ^a   Snead, Wanda L ^a   Neal, Doss W ^a   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood glucose; Incretin; Muscle glucose uptake; Net hepatic glucose uptake

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; SOMATOSTATIN; TRITIUM;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOG; FEMALE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOGEN SYNTHESIS; LIVER BLOOD FLOW; LIVER LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSPORT KINETICS;

EID: 0037403938     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00503.2002     Document Type: Article

References (52)

1. Agerso H, Jensen LB, Elbrond B, Rolan P, and Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45: 195-202, 2002.
2. Ahren B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 20: 642-651, 1998.
3. Ahren B and Pacini G. Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. Am J Physiol Endocrinol Metab 277: E996-E1004, 1999.
4. Balkan B and Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279: R1449-R1454, 2000.
5. Burcelin R, Da Costa A, Drucker D, and Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50: 1720-1728, 2001.
6. Chu CA, Sindelar DK, Neal DW, Allen EJ, Donahue EP, and Cherrington AD. Comparison of the direct and indirect effects of epinephrine on hepatic glucose production. J Clin Invest 99: 1044-1056, 1997.
7. D'Alessio DA, Kahn SE, Leusner CR, and Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93: 2263-2266, 1994.
8. D'Alessio DA, Prigeon RL, and Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulin independent processes. A physiological role of glucagonlike peptide I. Diabetes 44: 1433-1437, 1995.
9. Deacon CF, Hughes TE, and Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagonlike peptide 1 in the anesthetized pig. Diabetes 47: 764-769, 1998.
10. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, and Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131, 1995.
11. Deacon CF, Pridal L, Klarskov L, Olesen M, and Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 271: E458-E464, 1996.
12. Deacon CF, Wamberg S, Bie P, Hughes TE, and Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172: 355-362, 2002.
13. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 50: 191-197, 1997.
14. DeLeon MJ, Chandurkar V, Albert SG, and Mooradian AD. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract 56: 101-106, 2001.
15. Dobbins RL, Davis SN, Neal DW, Cobelli C, Jaspan J, and Cherrington AD. Compartmental modeling of glucagon kinetics in the conscious dog. Metabolism 44: 452-459, 1995.
16. Edwards CM, Edwards AV, and Bloom SR. Cardiovascular and pancreatic endocrine responses to glucagon-like peptide1(7-36) amide in the conscious calf. Exp Physiol 82: 709-716, 1997.
17. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, and Bloom SR. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281: E155-E161, 2001.
18. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, and Roth J. Glucagon-like peptide 1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135: 2070-2075, 1994.
19. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, and Zdravkovic M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a singledose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25: 1398-1404, 2002.
20. Freyse EJ, Becher T, El-Hag O, Knospe S, Goke B, and Fischer U. Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs. Diabetes 46: 824-828, 1997.
21. Freyse EJ, Knospe S, Becher T, El Hag O, Goke B, and Fischer U. Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Metabolism 48: 134-137, 1999.
22. Fürnsinn C, Ebner K, and Waldhäusl W. Failure of GLP-1(736)amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38: 864-867, 1995.
23. Galassetti P, Shiota M, Zinker BA, Wasserman DH, and Cherrington AD. A negative arterial-portal venous glucose gradient decreases skeletal muscle glucose uptake. Am J Physiol Endocrinol Metab 275: E101-E111, 1998.
24. Holst JJ. Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr Med Chem 6: 1005-1017, 1999.
25. Hsieh PS, Moore MC, Neal DW, Emshwiller M, and Cherrington AD. Rapid reversal of the effects of the portal signal under hyperinsulinemic conditions in the conscious dog. Am J Physiol Endocrinol Metab 276: E930-E937, 1999.
26. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, and Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 43: 104-108, 1994.
27. Imeryuz N, Yegen BC, Bozkurt A, Villanueva-Peñacarrillo ML, and Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: G920-G927, 1997.
28. Kieffer TJ and Habener JF. The glucagon-like peptides. Endocr Rev 20: 876-913, 1999.
29. Kieffer TJ, McIntosh CH, and Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596, 1995.
30. Lautt WW. The HISS story overview: a novel hepatic neurohumoral regulation of peripheral insulin sensitivity in health and diabetes. Can J Physiol Pharmacol 77: 553-562, 1999.
31. López-Delgado MI, Morales M, Villanueva-Peñacarrillo MIL, Malaisse WJ, and Valverde I. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology 139: 2811-2817, 1998.
32. Massimino SP, McBurney MI, Field CJ, Thomson AB, Keelan M, Hayek MG, and Sunvold GD. Fermentable dietary fiber increases GLP-1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. J Nutr 128: 1786-1793, 1998.
33. Miki H, Namba M, Nishimuri T, Mineo I, Matsumura T, Miyagawa J, Nakajima H, Kuwajima M, Hanafusa T, and Matsuzawa Y. Glucagon-like peptide-1 (7-36) amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochem Biophys Acta 1312: 132-136, 1996.
34. Moore MC, Hsieh PS, Neal DW, and Cherrington AD. Nonhepatic response to portal glucose delivery in conscious dogs. Am J Physiol Endocrinol Metab 279: E1271-E1277, 2000.
35. Myers SR, McGuinness OP, Neal DW, and Cherrington AD. Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration. J Clin Invest 87: 930-939, 1991.
36. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, and Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol Endocrinol Metab 271: E808-E813, 1996.
37. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, and Hellstrom PM. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23: 304-311, 1999.
38. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, and Uchida K. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 80: 14-21, 2000.
39. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, and Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 61: 149-154, 1996.
40. Ørskov L, Holst JJ, Moller J, Ørskov C, Moller N, Alberti KGMM, and Schmitz O. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 1227-1232, 1996.
41. Qualmann C, Nauck MA, Holst JJ, Orskov C, and Creutzfeldt W. Insulinotropic actions of intravenous glucagonlike peptide-1 (GLP-1)[7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32: 13-16, 1995.
42. Ryan AS, Eagan JM, Habener JF, and Elahi D. Insulinotropic hormone glucagon-like peptide-1(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83: 2399-2404, 1998.
43. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvill V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, and Giacca A. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48: 1045-1053, 1999.
44. Satake S, Moore MC, Converse M, Farmer B, Neal DW, and Cherrington AD. Direct and indirect effects of insulin on glucose uptake and storage by the liver. Diabetes 51: 1663-1671, 2002.
45. Shiota M, Jackson P, Galassetti P, Scott M, Neal DW, and Cherrington AD. Combined intraportal infusion of acetylcholine and adrenergic blockers augments net hepatic glucose uptake. Am J Physiol Endocrinol Metab 278: E544-E552, 2000.
46. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89: 8641-8645, 1992.
47. Toft-Nielson M, Madsbad S, and Holst JJ. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45: 552-556, 1996.
48. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A, and Villanueva-Penacarrillo ML. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349: 313-316, 1994.
49. Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, Holst JJ, and Rizza RA. Effect of glucagon-like peptide1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes 50: 565-572, 2001.
50. Vella A, Shah P, Basu R, Basu A, Holst JJ, and Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49: 611-617, 2000.
51. Villanueva-Peñacarrillo ML, Alcántara AI, Clemente F, Delgado E, and Valverde I. Potent glycogenic effect of GLP1(7-36)amide in rat skeletal muscle. Diabetologia 37: 1163-1166, 1994.
52. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, and Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609-613, 2001.